Breakthrough Prize Foundation awarded the Life Sciences prize to teams credited with pioneering gene therapies for two genetic disease areas. The coverage highlights Jean Bennett, Albert Maguire, and Katherine High (University of Pennsylvania) for retinal blindness work and Swee Lay Thein, with Stuart Orkin (Harvard) and colleagues, for gene discovery and translation toward fetal hemoglobin production in beta thalassemia and sickle cell disease. The story underscores that early gene therapy development required building tools and models before clinical durability challenges could be addressed. It also ties the recognition to real-world impact, noting the retinal gene therapy is currently in use in the US, Canada, Australia, and Switzerland. While awards are not regulatory milestones, the sector signal is validation of translational pathways—gene identification, delivery method maturation, and conversion from bench to bedside—that continue to guide new therapeutic development.